- Home
- GNLX vs AGEN Comparison
GNLX vs AGEN Comparison
Compare GNLX & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNLX
- AGEN
- Stock Information
- Founded
- GNLX 2001
- AGEN 1994
- Country
- GNLX United States
- AGEN United States
- Employees
- GNLX N/A
- AGEN N/A
- Industry
- GNLX Biotechnology: Pharmaceutical Preparations
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GNLX Health Care
- AGEN Health Care
- Exchange
- GNLX Nasdaq
- AGEN Nasdaq
- Market Cap
- GNLX 85.0M
- AGEN 96.2M
- IPO Year
- GNLX 2023
- AGEN 2000
- Fundamental
- Price
- GNLX $3.13
- AGEN $3.82
- Analyst Decision
- GNLX Strong Buy
- AGEN Buy
- Analyst Count
- GNLX 4
- AGEN 3
- Target Price
- GNLX $18.25
- AGEN $10.50
- AVG Volume (30 Days)
- GNLX 80.9K
- AGEN 399.9K
- Earning Date
- GNLX 11-14-2024
- AGEN 03-13-2025
- Dividend Yield
- GNLX N/A
- AGEN N/A
- EPS Growth
- GNLX N/A
- AGEN N/A
- EPS
- GNLX N/A
- AGEN N/A
- Revenue
- GNLX $8,000.00
- AGEN $160,427,000.00
- Revenue This Year
- GNLX N/A
- AGEN N/A
- Revenue Next Year
- GNLX N/A
- AGEN $36.13
- P/E Ratio
- GNLX N/A
- AGEN N/A
- Revenue Growth
- GNLX N/A
- AGEN 59.00
- 52 Week Low
- GNLX $1.60
- AGEN $2.50
- 52 Week High
- GNLX $12.12
- AGEN $19.69
- Technical
- Relative Strength Index (RSI)
- GNLX 68.05
- AGEN 65.58
- Support Level
- GNLX $2.25
- AGEN $3.08
- Resistance Level
- GNLX $2.57
- AGEN $3.29
- Average True Range (ATR)
- GNLX 0.25
- AGEN 0.27
- MACD
- GNLX 0.06
- AGEN 0.10
- Stochastic Oscillator
- GNLX 71.31
- AGEN 93.28
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).